Skip to Content

New Drug Approvals Archive - May 2005

May 2005

Vaccinia (vaccinia immune globulin intravenous (human)) Injection

Date of Approval: May 2, 2005
Company: DynPort Vaccine Company LLC
Treatment for: Smallpox Vaccine Reaction

Vaccinia Immune Globulin Intravenous (Human) (VIGIV) indicated for the treatment of complications from smallpox vaccination

Gammagard Liquid (immune globulin infusion (human)) Solution

Date of Approval: May 2, 2005
Company: Baxter Healthcare Corporation
Treatment for: Primary Immunodeficiency Syndrome

Gammagard (immune globulin infusion (human)) is an immune globulin infusion (human) indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older.

Boostrix (tetanus, diphtheria, acellular pertussis vaccine (Tdap))

Date of Approval: May 3, 2005
Company: GlaxoSmithKline Biologicals
Treatment for: Diphtheria Prophylaxis, Tetanus Prophylaxis, Pertussis Prophylaxis

Boostrix is a combination vaccine that provides a booster immunization against pertussis (whooping cough) in combination with tetanus and diphtheria.

Triglide (fenofibrate) Tablets

Date of Approval: May 7, 2005
Company: SkyePharma PLC
Treatment for: Hyperlipoproteinemia, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Hyperlipoproteinemia Type IV (Elevated VLDL), Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL), Hypertriglyceridemia

Triglide (fenofibrate) is a lipid-regulating agent for the treatment of hypercholesterolemia and hypertriglyceridemia.

Proquin XR (ciprofloxacin) Extended-Release Tablets

Date of Approval: May 19, 2005
Company: Depomed, Inc.
Treatment for: Urinary Tract Infection

Proquin XR (ciprofloxacin) is an extended release fluoroquinolone antibiotic indicated for the treatment of urinary tract infections.

Focalin XR (dexmethylphenidate) Extended-Release Capsules

Date of Approval: May 26, 2005
Company: Novartis Pharmaceuticals Corporation
Treatment for: Attention Deficit Disorder

Focalin XR (dexmethylphenidate) is a once-daily extended-release form of Focalin indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults, adolescents and children.

Naglazyme (galsulfase) - formerly Aryplase

Date of Approval: May 31, 2005
Company: BioMarin Pharmaceutical Inc.
Treatment for: Mucopolysaccharidosis Type VI

Naglazyme (galsulfase) is an enzyme-replacement therapy for treatment of mucopolysaccharidosis VI (MPS VI), an inherited, life-threatening lysosomal storage disorder caused by a deficiency of the lysosomal enzyme N-acetylgalactosamine 4-sulfatase (also known as arylsulfatase B).

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.